arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
March 13, 2015
Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.
The presentation will be webcast live and may be accessed by visiting the ‘News & events’ section of the Company’s website at www.argen-x.com. A replay of this webcast will be available for 90 days following the presentation.